|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.96 - 5.05|
|52 Week Range||3.66 - 6.64|
|PE Ratio (TTM)||-3.50|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.60|
DURHAM, N.C., Sept. 20, 2017-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief ...
DURHAM, N.C., Sept. 12, 2017-- Chimerix, a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chimerix, Inc. Here are 5 ETFs with the largest exposure to CMRX-US. Comparing the performance and risk of Chimerix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)